Latest:

Fat Pitch Financials

Special situation stocks and value investing

Stock Quote

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

G1 Therapeutics Inc (NQ: GTHX )

7.910 -0.190 (-2.35%)
Streaming Delayed Price Updated: 4:00 PM EST, Feb 3, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 917,415
Open 7.990
Bid (Size) 7.830 (3)
Ask (Size) 8.000 (2)
Prev. Close 8.100
Today's Range 7.750 - 8.100
52wk Range 3.840 - 17.49
Shares Outstanding 42,705,532
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Benzinga's Top Ratings Upgrades, Downgrades For January 30, 2023
 
Via Benzinga
G1 Therapeutics Announces Upcoming 2023 Readouts from its Phase 2 and Pivotal Phase 3 Clinical Trials of Trilaciclib
From G1 Therapeutics
Via Globe NewsWire

Performance

YTD
+38.05%
+38.05%
1 Month
+45.14%
+45.14%
3 Month
-4.93%
-4.93%
6 Month
-39.20%
-39.20%
1 Year
-16.38%
-16.38%

More News

Read More
Initial Results from Phase 2 Mechanism of Action Trial in Early-Stage Triple Negative Breast Cancer Show that a Single Dose of Trilaciclib Favorably Alters the Tumor Microenvironment
From G1 Therapeutics
Via Globe NewsWire
Benzinga's Top Ratings Upgrades, Downgrades For January 5, 2023
Via Benzinga
G1 Therapeutics Reveals An Early Cut Data From Bladder Cancer Trial
Via Benzinga
Big Developments Set to be Unveiled at This Year’s San Antonio Breast Cancer Symposium (SABCS)
Via FinancialNewsMedia
G1 Therapeutics Announces Closing of Offering of Common Stock
From G1 Therapeutics
Via Globe NewsWire
Nasdaq Down 0.5%; Clearfield Shares Spike Higher
Via Benzinga
G1 Therapeutics: Q3 Earnings Insights
Via Benzinga
Why InMed Pharmaceuticals Shares Tumbled 28%; Here Are 67 Biggest Movers From Friday
Via Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
Via Benzinga
Why PaxMedica Shares Are Trading Higher By Over 53%? Here Are 47 Stocks Moving In Friday's Mid-Day Session
Via Benzinga
Nasdaq Turns Lower; Crude Oil Down Over 3%
Via Benzinga
Delta Apparel, Farfetch, American Software And Some Other Big Stocks Moving Lower On Friday
Via Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
Why Farfetch Shares Are Trading Lower; Here Are 26 Stocks Moving Premarket
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
Via InvestorPlace
G1 Therapeutics Announces Pricing of Offering of Common Stock
From G1 Therapeutics
Via Globe NewsWire
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
G1 Therapeutics Announces Proposed Public Offering of Common Stock
From G1 Therapeutics
Via Globe NewsWire
G1 Therapeutics Says Its Lead Candidate May Cut Adverse Events Of Gilead's Breast Cancer Drug
Via Benzinga
Why Tupperware Brands Shares Dipped Around 42%; Here Are 89 Biggest Movers From Yesterday
Via Benzinga
Why Benefitfocus Shares Are Trading Higher By Around 48%? Here Are 64 Stocks Moving In Wednesday's Mid-Day Session
Via Benzinga
G1 Therapeutics Provides Third Quarter 2022 Financial Results and Operational Highlights
From G1 Therapeutics
Via Globe NewsWire
Initial Results from Phase 2 Trial Demonstrate Potential of Trilaciclib to Reduce Adverse Events Related to an Antibody Drug Conjugate (ADC)
From G1 Therapeutics
Via Globe NewsWire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.